Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-02-27

FDA Approved: MYLOTARG — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Mylotarg (gemtuzumab ozogamicin) submitted by Wyeth Pharmaceuticals (Pfizer), updating its labeling for acute my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mylotarg (gemtuzumab ozogamicin)

Snippet

SUPPL AP for MYLOTARG (GEMTUZUMAB OZOGAMICIN)